Atlas Trials

Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma

Clinical trial NCT06034977 · UNKNOWN

Trial details

NCT number
NCT06034977
Sponsor
Chang Gung Memorial Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatocellular Carcinoma
Start date
2023-12-01
Primary completion
2026-07-23
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.